Notice: eScholarship will undergo scheduled maintenance from Tuesday, January 21 to Wednesday, January 22. Some functionality may not be available during this time. Learn more at eScholarship Support.
Self‐ and study partner–reported cognitive decline in older adults without dementia: The role of α‐synuclein and amyloid biomarkers in the Alzheimer's Disease Neuroimaging Initiative
Subjective cognitive decline (SCD) may be an early marker of Alzheimer's disease (AD) pathology. Until recently, it was impossible to measure biomarkers specific for α-synuclein pathology; therefore, its association with subjective reports of cognitive decline is unknown.
Methods
Alzheimer's Disease Neuroimaging Initiative participants without dementia (n = 918) were classified as positive or negative for amyloid beta (Aβ+ or Aβ-) and α-synuclein (α-syn+ or α-syn-) biomarkers. Self- and study partner-reported cognitive decline was measured with the Everyday Cognition (ECog) questionnaire.
Results
Per self-report, Aβ+/α-syn+ had the greatest cognitive decline. Aβ-/α-syn+ did not differ from Aβ-/α-syn- across ECog scores. Study partner-reported results had a similar pattern, but Aβ+/α-syn- and Aβ+/α-syn+ did not differ across ECog scores. Mild cognitive impairment classification moderated the study partner-reported memory score.
Discussion
While α-syn+ alone did not increase subjective reports of cognitive decline, Aβ+/α-syn+ had the most self- and study partner-rated cognitive decline. Therefore, the presence of multiple pathologies was associated with greater SCD.
Highlights
Cerebrospinal fluid α-synuclein (α-syn) seed amplification assay was used to determine α-syn positivity. Amyloid beta (Aβ)-/α-syn-, Aβ-/α-syn+, Aβ+/α-syn-, and Aβ+/α-syn+ biomarker groups were created. Aβ+/α-syn+ had greater subjective cognitive decline (SCD) than the other biomarker groups. Aβ-/α-syn+ did not differ from Aβ-/α-syn- across self- or study-partner reported SCD scores. Study partner-reported subjective memory results were largely driven by participants with mild cognitive impairment.
